Abbott departs Emergent B-cell malignancy drug deal
This article was originally published in Scrip
Executive Summary
Abbott delivered a lump of coal to Emergent BioSolutions this week, ending the firms' deal to develop and commercialize TRU-016, a humanized anti-CD37 mono-specific protein therapeutic under investigation to treat chronic lymphocytic leukaemia (CLL) and non-Hodgkin's lymphoma (NHL).